Velan Capital Investment Management LP increased its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 5.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,667,800 shares of the company's stock after acquiring an additional 88,800 shares during the quarter. Protara Therapeutics comprises approximately 7.3% of Velan Capital Investment Management LP's portfolio, making the stock its 4th largest holding. Velan Capital Investment Management LP owned about 4.32% of Protara Therapeutics worth $7,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new stake in Protara Therapeutics during the 4th quarter worth $111,000. Bank of America Corp DE raised its stake in Protara Therapeutics by 53,013.9% during the 4th quarter. Bank of America Corp DE now owns 194,397 shares of the company's stock worth $1,026,000 after acquiring an additional 194,031 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Protara Therapeutics during the 4th quarter worth $802,000. Geode Capital Management LLC raised its stake in Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock worth $948,000 after acquiring an additional 9,553 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Protara Therapeutics by 2,479.2% during the 4th quarter. Millennium Management LLC now owns 371,453 shares of the company's stock worth $1,961,000 after acquiring an additional 357,051 shares in the last quarter. 38.13% of the stock is currently owned by institutional investors and hedge funds.
Protara Therapeutics Trading Up 1.7%
Shares of Protara Therapeutics stock traded up $0.06 on Wednesday, reaching $3.23. 76,416 shares of the stock were exchanged, compared to its average volume of 318,751. Protara Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $10.48. The business has a fifty day moving average price of $3.11 and a two-hundred day moving average price of $3.48. The firm has a market capitalization of $124.42 million, a PE ratio of -1.99 and a beta of 1.52.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Research analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.
Analyst Ratings Changes
Separately, Jones Trading raised shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 price objective on the stock in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $19.60.
Get Our Latest Report on TARA
Protara Therapeutics Profile
(
Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Further Reading
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
